XFOR Stock Forecast: X4 Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.01
+1.69% on the day

The median 12-month analyst price target for X4 Pharmaceuticals, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 65 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$302.3M
Ticker Nerd rank
65/ 100
Median analyst target
$12
Analysts covering
5
Revenue$8.8M+346.3% y/y
Operating income−$16.4M
Net income−$16.2M
Free cash flow−$25.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.5%
1M
−0.3%
YTD
−24.8%
1Y
−18.6%
From 52W high
−35.5%
From 52W low
+22.9%
$2.45
$4.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores X4 Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
65/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
86
Growth
73
Momentum
70
Volatility
53
Quality
51
Value
46
Accruals
33
Issuance
24

Revisions (86): Analysts have, on balance, been raising their forecasts.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XFOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XFOR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26XFORHigh $13Median $12Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$10
Low
$12
Median
$13
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 July 2026Wells FargoInitiatesOverweight$11
2 June 2026Leerink PartnersInitiatesOutperform—
9 Mar 2026GuggenheimInitiatesBuy—
5 Dec 2025StifelMaintainsBuy—
10 Nov 2025HC Wainwright & Co.MaintainsBuy—
29 Aug 2025StifelMaintainsBuy—
13 Aug 2025HC Wainwright & Co.MaintainsBuy—
2 May 2025HC Wainwright & Co.MaintainsBuy—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
26 Mar 2025Cantor FitzgeraldReiteratesOverweight—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.MaintainsBuy—
14 Nov 2024StifelMaintainsBuy—
28 June 2024HC Wainwright & Co.ReiteratesBuy—
31 May 2024Cantor FitzgeraldReiteratesOverweight—
30 Apr 2024HC Wainwright & Co.MaintainsBuy—
22 Mar 2024HC Wainwright & Co.ReiteratesBuy—
12 Dec 2023B. Riley SecuritiesDowngradeNeutral—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for XFOR.

Market Radar

This page is one stock. Monday covers all of them.

XFOR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XFOR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, X4 Pharmaceuticals, Inc. returned −18.6% against +6.9% for the S&P 500, dividends included.

XFOR vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Jan 26Apr 26Jul 26Oct 26XFORS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XFOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.5×

Cheaper than 85% of US stocks

Price / sales
18.2×

Cheaper than 8% of US stocks

Price / book
2.2×

Cheaper than 40% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
81.6%

Higher than 92% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−80.3%

Higher than 16% of US stocks

Return on assets
−23.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • X4 Pharmaceuticals, Inc. has a market value of $302.3M and an enterprise value of $191.8M.

  • Revenue in the twelve months to 30 June 2026: $15.8M. The latest quarter grew 346.3% year on year.

  • Net income over the same four quarters: −$90.1M, a −568.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$88.7M.

  • Shares outstanding: 96.1M.

  • Trailing P/E: 5.5×.

  • X4 Pharmaceuticals, Inc. employs 45 people — $352K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

XFOR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XFORX4 Pharmaceuticals, Inc.$302.3M65
SPRYARS Pharmaceuticals, Inc.$297.6M13
EVMNEvommune, Inc.$291.1M11
SLBTSL Science Holding Ltd.$308.4M0
BNTCBenitec Biopharma, Inc.$285.9M39
GLSIGreenwich LifeSciences, Inc.$282.6M53
PROKProKidney Corp.$313.9M17

Take a look at XFOR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own X4 Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about XFOR

What is the XFOR stock price forecast for 2026-2027?

The median 12-month analyst price target for X4 Pharmaceuticals, Inc. is $12, with estimates ranging from $10 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XFOR stock a buy right now?

Of the 5 analysts covering X4 Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks X4 Pharmaceuticals, Inc. 65 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XFOR?

As at 21 Nov 2026, X4 Pharmaceuticals, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (86 of 100).

Will XFOR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $12, and Ticker Nerd's factor model ranks X4 Pharmaceuticals, Inc. 65 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XFOR stock forecast for 2030?

No analyst covering X4 Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XFOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $13 over the next 12 months.

How has XFOR stock performed over the past year?

X4 Pharmaceuticals, Inc. returned -18.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does X4 Pharmaceuticals, Inc. do?

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders. The company’s core work centers on CXCR4-targeted medicines, including mavorixafor, an oral small-molecule antagonist designed to improve immune cell trafficking and address conditions marked by chronic neutropenia and immunodeficiency.

Company

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases of the immune system and rare hematology disorders. The company’s core work centers on CXCR4-targeted medicines, including mavorixafor, an oral small-molecule antagonist designed to improve immune cell trafficking and address conditions marked by chronic neutropenia and immunodeficiency. X4 Pharmaceuticals markets XOLREMDI in the United States and continues to evaluate mavorixafor in additional indications through clinical development programs. Its portfolio and commercial activity place it at the intersection of immunology, hematology, and rare-disease care, serving patients with significant unmet medical needs. Based in Boston, Massachusetts, X4 Pharmaceuticals plays a specialized role in the biotechnology market by focusing on treatments for underserved patient populations.

CEO Dr. Paula Ragan Ph.D. · 45 employees · United States · https://www.x4pharma.com